Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib and Durvalumab in KRAS G12C-mutated Advanced Cancers
NCT05848843Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adagrasib in non-small cell lung cancer (NSCLC) and gastrointestinal cancer (2 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events, Graded According to NCI CTCAE v5.0. Planned start Apr 2023; status: withdrawn.
02
Drugs
adagrasib
03
Conditions
non-small cell lung cancer (NSCLC)gastrointestinal cancer
Beyond the preview
Go deeper on NCT05848843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05848843.